92 related articles for article (PubMed ID: 2581123)
1. Conformational features of calcium channel agonist and antagonist analogs of nifedipine.
Langs DA; Triggle DJ
Mol Pharmacol; 1985 May; 27(5):544-8. PubMed ID: 2581123
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel modulation: ability to inhibit or promote calcium influx resides in the same dihydropyridine molecule.
Thomas G; Gross R; Schramm M
J Cardiovasc Pharmacol; 1984; 6(6):1170-6. PubMed ID: 6084776
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the dihydropyridine Ca2+ antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data.
Fossheim R
J Med Chem; 1986 Feb; 29(2):305-7. PubMed ID: 3005572
[TBL] [Abstract][Full Text] [Related]
4. Activation of calcium channels by novel 1,4-dihydropyridines. A new mechanism for positive inotropics or smooth muscle stimulants.
Schramm M; Thomas G; Towart R; Franckowiak G
Arzneimittelforschung; 1983; 33(9):1268-72. PubMed ID: 6196037
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates.
Iqbal N; Akula MR; Vo D; Matowe WC; McEwen CA; Wolowyk MW; Knaus EE
J Med Chem; 1998 May; 41(11):1827-37. PubMed ID: 9599233
[TBL] [Abstract][Full Text] [Related]
6. Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists.
Zhorov BS; Folkman EV; Ananthanarayanan VS
Arch Biochem Biophys; 2001 Sep; 393(1):22-41. PubMed ID: 11516158
[TBL] [Abstract][Full Text] [Related]
7. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
Shan R; Velazquez C; Knaus EE
J Med Chem; 2004 Jan; 47(1):254-61. PubMed ID: 14695839
[TBL] [Abstract][Full Text] [Related]
8. The 1,4-dihydropyridine receptor: a regulatory component of the Ca2+ channel.
Triggle DJ; Janis RA
J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S949-55. PubMed ID: 6085383
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and calcium channel antagonist activity of new 1,4-dihydropyridines containing 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent.
Davood A; Mansouri N; Rerza Dehpour A; Shafaroudi H; Alipour E; Shafiee A
Arch Pharm (Weinheim); 2006 Jun; 339(6):299-304. PubMed ID: 16649160
[TBL] [Abstract][Full Text] [Related]
10. [Molecular tools for the study of calcium channels: synthesis and evaluation of biological activity of new derivatives of 4-aryl-1,4-dihydropyridine groups].
Soldatov NM
Biokhimiia; 1988 Jul; 53(7):1059-68. PubMed ID: 2846077
[TBL] [Abstract][Full Text] [Related]
11. Human red blood cells--an ideal model system for the action of calcium agonists and antagonists.
Stimpel M; Neyses L; Locher R; Groth H; Vetter W
J Hypertens Suppl; 1984 Dec; 2(3):S577-80. PubMed ID: 6085891
[TBL] [Abstract][Full Text] [Related]
12. Receptor model for the molecular basis of tissue selectivity of 1, 4-dihydropyridine calcium channel drugs.
Langs DA; Strong PD; Triggle DJ
J Comput Aided Mol Des; 1990 Sep; 4(3):215-30. PubMed ID: 2177783
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and calcium channel antagonist activity of 1,2-dihydropyridyl analogues of nifedipine.
Wynn H; Ramesh M; Matowe WC; Wolowyk MW; Knaus EE
Drug Des Deliv; 1988 Nov; 3(3):245-56. PubMed ID: 2855579
[TBL] [Abstract][Full Text] [Related]
14. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 1,2-dihydropyridyl in place of the 1,4-dihydropyridyl moiety.
Soboleski DA; Li-Kwong-Ken MC; Wynn H; Triggle CR; Wolowyk MW; Knaus EE
Drug Des Deliv; 1988 Feb; 2(3):177-89. PubMed ID: 2855573
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of the binding of [3H]nitrendipine to rabbit ventricular membranes: modification by other Ca++ channel antagonists and by the Ca++ channel agonist Bay K 8644.
Janis RA; Sarmiento JG; Maurer SC; Bolger GT; Triggle DJ
J Pharmacol Exp Ther; 1984 Oct; 231(1):8-15. PubMed ID: 6208356
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4-pyridyl and 3-arylethyloxycarbonyl substituents.
Akula MR; Matowe WC; Wolowyk MW; Knaus EE
Drug Des Deliv; 1990 Dec; 7(1):11-7. PubMed ID: 2096831
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4(5)-chloro-2-methyl-5(4)-imidazolyl substituent.
Davood A; Khodarahmi G; Alipour E; Dehpour K; Amini M; Shafiee A
Boll Chim Farm; 2001; 140(6):381-6. PubMed ID: 11822226
[TBL] [Abstract][Full Text] [Related]
19. Molecular level model for the agonist/antagonist selectivity of the 1,4-dihydropyridine calcium channel receptor.
Langs DA; Kwon YW; Strong PD; Triggle DJ
J Comput Aided Mol Des; 1991 Apr; 5(2):95-106. PubMed ID: 1651370
[TBL] [Abstract][Full Text] [Related]
20. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.
Glossmann H; Ferry DR; Goll A; Rombusch M
J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S608-21. PubMed ID: 6083403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
